Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astepro in Seasonal Allergic Rhinitis
NCT00720278Phase 3Completed
- Sponsor
- Meda
- Start
- Aug 2007
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azelastine in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Meda. Primary endpoint: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score at 14 days. Started Aug 2007; status: completed.
02
Drugs
azelastine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00720278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00720278.